The Cost of Not Knowing: Why Reproductive Healthcare Needs a New Information Model

Reproductive health often does not begin with a diagnosis. It begins with uncertainty.

A cycle that feels different. Pain that keeps returning. Infections go undiagnosed and mistreated. Months of trying to conceive while being told to wait a little longer. Another consultation. Another test. Another answer that still does not explain what is happening inside your own body. Reproductive healthcare is still too uncertain.

Clinicians are often asked to make time-sensitive decisions based on isolated measurements: a blood test on one day, an ultrasound at one point, or symptom reporting shaped by memory, stress, shame, and the pressure to explain complex symptoms in a short consultation. But reproductive physiology does not move in isolated moments. It changes across hours, days, and cycles.

When the body is dynamic, and the data is static, uncertainty becomes part of the care model. Women feel the consequences before anyone else sees the system cost.

The hidden cost starts before treatment

In fertility care, most conversations focus on treatment: IVF, hormone therapy, embryo transfers, medication, or surgery. These treatments matter. But the highest hidden cost often begins before treatment. It starts with not knowing.

Delayed diagnosis in conditions such as polycystic ovary syndrome, endometriosis, and luteal phase dysfunction can push women through years of consultations, repeated medication, emotional exhaustion, and eventually assisted reproduction. Pregnancy may still have been possible, but the biological patterns behind the difficulty were not understood early enough.

Fertility should not only be viewed as a treatment market. Women do not need more pressure, more guessing, or faster escalation into expensive procedures. They need earlier insight. They need clarity before the situation becomes a medical, financial, and emotional crisis.

The numbers already show how expensive uncertainty can become.

A failed IVF cycle can still cost patients an estimated €2,500 to €6,000 out of pocket in the Netherlands. In the United Kingdom, private treatment can cost around €6,500 to €12,000 per failed cycle. In Hungary, the cost is lower, but still significant at an estimated €1,200 to €3,500 per failed cycle.

The real metric is not one cycle. It is the number of cycles required to achieve a successful pregnancy.

With IVF success rates around 25% to 35% per cycle, patients often need multiple attempts. Every failed cycle carries both clinical and emotional costs. It means medication, waiting, hope, fear, grief, and then the question nobody wants to ask again: do we try one more time?

For healthcare systems, delayed diagnosis increases specialist care, repeated diagnostics, surgery, fertility treatments, and long-term disease management. In patients, it affects relationships, mental health, career planning, savings, and trust in their own bodies.

A failed cycle touches everything: the clinic, the wallet, the relationship, the nervous system, and the way a woman sees herself.

Reproductive healthcare still relies too much on snapshots

The current model gives clinicians partial context.

Blood tests provide snapshots. Ultrasounds provide snapshots. Calendar apps provide estimates. Symptom tracking depends on what a woman notices, remembers, and feels safe sharing. These tools matter, but the gaps between them matter too.

The ovulatory window, implantation readiness, vaginal environment, infection risk, and luteal phase stability all involve biological shifts that can happen between appointments. Important information may appear when nobody is measuring.

Fertility interventions are often time-dependent. A correct intervention at the wrong biological moment can lead to the same outcome as no intervention at all.

I find that hard to accept. When a cycle fails, the woman often carries the emotional weight and wonders what she did wrong. She questions her body and starts to lose trust. But sometimes her body did not fail. It’s the system that simply did not have enough information at the right time.

Women’s health needs a better biological context

At YON E, we are building around one belief: women’s health needs direct, biological insight. 

We are also developing a clinical decision-support physiology monitoring system focused on vaginal biomarker monitoring, including vaginal pH and basal body temperature. The aim is to add physiological context to reproductive care, so clinicians and women can better understand cycle timing, ovulation confirmation, vaginal environment readiness, infection risk, and pre-treatment stabilization.

The device is not intended to treat infertility. Its role is to provide additional physiological information that may support clinical decision-making and earlier understanding of reproductive health patterns. Clinical decisions remain with healthcare professionals.

The change sounds simple, but the impact can be significant. Less reacting after failure. More understanding before escalation.

In healthcare innovation, people often ask whether a new technology can replace an existing treatment. For YON E, I would ask something else: can better biological information reduce unnecessary escalation, mistimed interventions, and repeated failed cycles?

Preventing even one failed cycle can reduce patient burden, clinical workload, and avoidable costs. The opportunity goes beyond fertility optimization. It reaches cost avoidance, workflow efficiency, patient retention, and better clinical decision-making.

For clinics, a better physiological context can support stronger timing decisions and more differentiated care. For insurers and health systems, earlier insight may prevent downstream intervention from becoming expensive. For patients, it can mean less time living in uncertainty.

The long-term value sits in what the market still lacks: measured biological data, longitudinal reproductive health patterns, clinical workflow integration, and a reproductive health dataset built with women in mind.

Trust has to come before adoption

Women’s health innovation often struggles because companies treat trust as something to solve at launch. It does not work like that.

You cannot ignore women for decades, underfund their research, normalize their pain, and then expect them to adopt a medical technology just because it exists. Women need education. Clinicians need evidence. Investors need to understand the economic logic behind it. Healthcare systems need validated endpoints.

YON E’s strategy combines clinical adoption with community building. The B2B pathway builds medical legitimacy. The B2C ecosystem builds patient readiness, education, and trust before the medical device enters the market. Some people call that complicated. I call it responsible.

Medical technologies often fail because they build the product first and only later try to find trust. We are building the relationship, the education, and the evidence before asking women and clinicians to adopt something new.

Women deserve earlier answers

For me, women’s health has never been theoretical. I have seen what happens when women are not protected, not believed, not guided, and not given the right information. I have seen how silence becomes normal. I have seen how women carry pain while still keeping families, careers, relationships, and entire lives moving. 

Uncertainty has a price. When a woman does not understand what is happening in her body, she is missing more than data and is losing time and money. Furthermore, she is losing her peace and even losing trust in herself.

Reproductive healthcare cannot be built only around more procedures. It has to be built around an earlier understanding. A woman should not have to wait years for her symptoms to be taken seriously. A clinician should not have to make time-critical decisions without an incomplete biological context. A healthcare system should not continue paying for late-stage interventions when earlier insight could reduce avoidable costs.

Women deserve more than late answers. They deserve information early enough to make different decisions.

At YON E, we are building for women who are tired of waiting for answers, and for clinicians who want more than fragments of information. Reproductive healthcare will not improve by asking women to wait longer, try again, or accept uncertainty as normal. It improves when we measure the right signals earlier. 

If you are a clinician, researcher, investor, or partner working toward better women’s health, we would be happy to start the conversation.

Roswitha Verwer 

Founder & CEO YON E